tiprankstipranks
Moderna initiated with a Neutral at Guggenheim
The Fly

Moderna initiated with a Neutral at Guggenheim

Guggenheim analyst Evan Wang initiated coverage of Moderna with a Neutral rating and no price target. COVID remains an important near-term driver, though "Moderna is not just a COVID story" with expansion to RSV, flu, oncology, therapeutics, and editing, says the analyst, who thinks 2023 guidance is "likely reflected in the stock." The key for 2023 is delivering on expectations for updated flu vaccine mRNA-1010 and while the firm’s "best guess is success," the analyst is more cautious than the Street and warns that "failure could lead to material downside revision."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on MRNA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles